Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482676 | 1.00 | ABCC9 (0.37) | ABCC9IDO1FLT1AHRALPL | |
| SCHEMBL8069749 | 0.87 | KDM1A (0.33) | ABCC9IDO1 | |
| SCHEMBL7762928 | 0.83 | — | — | |
| SCHEMBL8071529 | 0.83 | ABCB1 (0.33) | ABCC9 | |
| SCHEMBL7258587 | 0.79 | KCNE1 (0.38) | ABCC9IDO1AHR | |
| SCHEMBL482484 | 0.79 | KCNE1 (0.47) | ABCC9 | |
| SCHEMBL7401102 | 0.75 | IDO1 (0.32) | IDO1 | |
| SCHEMBL6274078 | 0.74 | IDO1 (0.40) | IDO1 | |
| SCHEMBL5868353 | 0.74 | IDO1 (0.40) | IDO1 | |
| SCHEMBL2869264 | 0.73 | KDM4E (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | disclosed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| US-7838553-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-23 | — | — | US | disclosed |
| US-7812183-B2 | Benzopyran derivatives as potassium channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-12 | — | — | US | disclosed |
| EP-1940516-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | Janssen Pharmaceutica, N.V. (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027780-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885IDO1 4077/4885FLT1 4067/4885 |
| US-20070072832-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | ABCC9 217/4885IDO1 4077/4885FLT1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.